Clinical Trial

Fibrinogen in Liver Transplant

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.
Trial Details
NCT Number NCT07265843
Lead Sponsor Trauma Hemostatis and Oxygenation Research (THOR) Network
Conditions Liver Transplant Surgery
Enrollment 60 participants
Start Date 2026-01-01
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05